CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Ion cyclotron resonance is a phenomenon related to the movement of ions in a magnetic field. It is used for accelerating ions in a cyclotron, and for measuring the masses of an ionized analyte in mass spectrometry, particularly with Fourier transform ion cyclotron resonance mass spectrometers. It can also be used to follow the kinetics of chemical reactions in a dilute gas mixture, provided these involve charged species.
(1999), "Conditioned Arising Evolves: Variation and Change in Textual Accounts of the Paticca-samupadda Doctrine", Journal of the International Association of Buddhist Studies, 22 (2) Jurewicz, Joanna (2000), "Playing with Fire: The pratityasamutpada from the perspective of Vedic thought", Journal of the Pali Text Society, 26: 77–103 Shulman, Eviatar (2008), "Early Meanings of Dependent-Origination" (PDF), Journal of Indian Philosophy, 36 (2): 297–317, doi:10.1007/s10781-007-9030-8, S2CID 59132368, archived from the original (PDF) on 10 October 2016 Gombrich, Richard (2009), "Chaper 9. Causation and non-random process", What the Buddha Thought, Equinox Jones, Dhivan Thomas (2009), "New Light on the Twelve Nidanas", Contemporary Buddhism, 10 (2): 241–259, doi:10.1080/14639940903239793, S2CID 145413087
=== Attention deficit hyperactivity disorder === Clonidine is used as a non-stimulant pharmacological treatment for ADHD and is USFDA-approved in its extended-release formulation as both a monotherapy and an adjunctive therapy to psychostimulants. Clinical guidelines and comparative-efficacy reviews regard psychostimulant medications (i.e., amphetamine and methylphenidate) as first-line pharmacotherapy for ADHD, while non-stimulant medications such as clonidine are recommended as second-line options because their effect sizes are smaller than those of psychostimulants. Non-stimulant medications, including clonidine, are typically used in individuals who do not respond adequately to psychostimulants, cannot tolerate psychostimulant adverse effects, have contraindications such as a high risk of psychostimulant misuse, or who have a preference for a non-stimulant treatment. α2 adrenoreceptor agonists (i.e., clonidine and guanfacine) are one class of non-stimulant medications that treat ADHD by stimulating receptors expressed in the prefrontal cortex, thereby enhancing cognitive control of behavior. Clonidine acts non-selectively at α2A, α2B and α2C receptor subtypes across the central nervous system, whereas guanfacine is selective for postsynaptic α2A adrenoreceptors, a difference that is believed to be partially responsible for clonidine's greater propensity for sedative and hypotensive side effects.
== Chemical synthesis == The first total synthesis of gliotoxin was achieved by Fukuyama and Kishi in 1976. Gliotoxin contains a total of four asymmetric centers along with two ring systems—hydrated benzene and epidithiapiperazinedione. Fukuyama and Kishi first synthesized the thioacetal 1 from glycine sarcosine anhydride via a six-step synthesis with an overall 30% yield. A Michael reaction of 4-carbo-tert-butoxybenzene oxide 2 in excess in a solvent of dimethyl sulfoxide (DMSO) containing Triton B at room temperature produced the alcohol 3 in 88% overall yield. It is expected that there would be a trans-opening of the epoxide ring for 2, so the resulting epimers would differ in the relative configuration of the thioacetal bridge and the alcoholic group depending on the orientation of compounds 1 and 2 in the transition state. It was theorized that the orientation of 1 and 2 that produced the alcohol 3 would be unfavorable in non-polar solvents. Thus, desired stereochemistry was assigned to the alcohol 3, and this compound was used in the further synthesis.
Sources: en.wikipedia.org
The PTI- and ETI-signaling pathways are used in conjunction with DAMPs to rapidly signal the rest of the plant to activate its innate immune response and fight off the invading pathogen or mediate the healing process from damage caused by trauma. Plant DAMPs and their receptors are characterized as:
==== Step 3: Termination ==== The last stage of translation occurs when a stop codon enters the A site. Then, the following steps occur: 1. The recognition of codons by release factors, which causes the hydrolysis of the polypeptide chain from the tRNA located in the P site 2. The release of the polypeptide chain 3. The dissociation and "recycling" of the ribosome for future translation processes A summary table of the key players in translation is found below:
EMS horses tend to become obese very easily, depositing fat in the crest, shoulders, loin, above the eyes, around the tail head, and the mammary glands or prepuce, even when the rest of the body appears to be in normal condition. Some horses may have regional adiposity, and others may even appear normal weight, so obesity is not a definitive clinical sign of a horse with EMS. Horses will be insulin resistant (IR), and may have hyperinsulinemia, have abnormal blood glucose, or abnormal insulin responses to glucose. IR predisposes the animal to laminitis, and horses with EMS may have had previous episodes in their history. Other signs suggesting EMS include elevated blood triglyceride levels and leptin levels, hypertension, and reproductive changes in mares (an increased diestrus period, and a lack of anestrus). Horses also occasionally show anemia and elevated gamma-glutamyl transpeptidase (GGT) levels.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.